Microglia and Astrocytes as Drug Targets

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (27 November 2023) | Viewed by 6331

Special Issue Editors


E-Mail Website
Guest Editor
Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia
Interests: multiple sclerosis; glia; neuroinflammation; myelin; lipid; protein

E-Mail Website
Guest Editor
Department of Neurosurgery, Rutgers University, Staged Research Building-Rm 144-145, 661 Hoes Lane West, Piscataway, NJ 08854, USA
Interests: neuroinflammation; glial cells; neurodegenerative diseases; Parkinson’s disease; glial morphology

Special Issue Information

Dear Colleagues,

Recent findings suggest that neuroinflammation is driven by the activation of microglia and astrocytes (gliosis) and escalates with demyelination or neurodegeneration in many neurodegenerative or demyelinating diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). In normal physiological condition, glial cells maintain homeostasis in and provide support to the central nervous system (CNS) and participate in the regulation of neuronal and synaptic functions. Upon activation, microglia and astrocytes can be either beneficial or detrimental based on the level or stages of activation. By enhancing beneficial and/or reducing detrimental aspects of glial activation, amelioration of neuroinflammation, demyelination and neurodegeneration can be achieved, although no such therapeutics exists based on our knowledge. Therefore, there is a crucial need to find new therapeutic products that can modulate glial activation to treat neuroinflammatory and neurodegenerative diseases in the future. This is the focus of this Special Issue, which will collect articles investigating microglia and astrocytes-specific drug candidates.

Dr. Monokesh K. Sen
Dr. Faheem Ullah
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuroinflammation
  • demyelination
  • gliosis
  • neuroprotection
  • neurodegeneration
  • therapeutic drug targets

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 7083 KiB  
Article
Cofilin Inhibitor Improves Neurological and Cognitive Functions after Intracerebral Hemorrhage by Suppressing Endoplasmic Reticulum Stress Related-Neuroinflammation
by Daniyah A. Almarghalani, Ghaith A. Bahader, Mohammad Ali, L. M. Viranga Tillekeratne and Zahoor A. Shah
Pharmaceuticals 2024, 17(1), 114; https://doi.org/10.3390/ph17010114 - 15 Jan 2024
Cited by 2 | Viewed by 2423
Abstract
Neuroinflammation after intracerebral hemorrhage (ICH) is a crucial factor that determines the extent of the injury. Cofilin is a cytoskeleton-associated protein that drives neuroinflammation and microglia activation. A novel cofilin inhibitor (CI) synthesized and developed in our lab has turned out to be [...] Read more.
Neuroinflammation after intracerebral hemorrhage (ICH) is a crucial factor that determines the extent of the injury. Cofilin is a cytoskeleton-associated protein that drives neuroinflammation and microglia activation. A novel cofilin inhibitor (CI) synthesized and developed in our lab has turned out to be a potential therapeutic agent for targeting cofilin-mediated neuroinflammation in an in vitro model of ICH and traumatic brain injury. The current study aims to examine the therapeutic potential of CI in a mouse collagenase model of ICH and examine the neurobehavioral outcomes and its mechanism of action. Male mice were subjected to intrastriatal collagenase injection to induce ICH, and sham mice received needle insertion. Various concentrations (25, 50, and 100 mg/kg) of CI were administered to different cohorts of the animals as a single intravenous injection 3 h following ICH and intraperitoneally every 12 h for 3 days. The animals were tested for neurobehavioral parameters for up to 7 days and sacrificed to collect brains for hematoma volume measurement, Western blotting, and immunohistochemistry. Blood was collected for cofilin, TNF-α, and IL-1β assessments. The results indicated that 50 mg/kg CI improved neurological outcomes, reversed post-stroke cognitive impairment, accelerated hematoma resolution, mitigated cofilin rods/aggregates, and reduced microglial and astrocyte activation in mice with ICH. Microglia morphological analysis demonstrated that CI restored the homeostasis ramification pattern of microglia in mice treated with CI. CI suppressed endoplasmic reticulum stress-related neuroinflammation by inhibiting inflammasomes and cell death signaling pathways. We also showed that CI prevented synaptic loss by reviving the pre- and post-synaptic markers. Our results unveil a novel therapeutic approach to treating ICH and open a window for using CI in clinical practice. Full article
(This article belongs to the Special Issue Microglia and Astrocytes as Drug Targets)
Show Figures

Figure 1

Review

Jump to: Research

24 pages, 6316 KiB  
Review
Sialic Acid Mimetic Microglial Sialic Acid-Binding Immunoglobulin-like Lectin Agonism: Potential to Restore Retinal Homeostasis and Regain Visual Function in Age-Related Macular Degeneration
by Michael J. Tolentino, Andrew J. Tolentino, Elizabeth M. Tolentino, Anitha Krishnan and Mohamed A. Genead
Pharmaceuticals 2023, 16(12), 1735; https://doi.org/10.3390/ph16121735 - 16 Dec 2023
Cited by 2 | Viewed by 2192
Abstract
Age-related macular degeneration (AMD), a leading cause of visual loss and dysfunction worldwide, is a disease initiated by genetic polymorphisms that impair the negative regulation of complement. Proteomic investigation points to altered glycosylation and loss of Siglec-mediated glyco-immune checkpoint parainflammatory and inflammatory homeostasis [...] Read more.
Age-related macular degeneration (AMD), a leading cause of visual loss and dysfunction worldwide, is a disease initiated by genetic polymorphisms that impair the negative regulation of complement. Proteomic investigation points to altered glycosylation and loss of Siglec-mediated glyco-immune checkpoint parainflammatory and inflammatory homeostasis as the main determinant for the vision impairing complications of macular degeneration. The effect of altered glycosylation on microglial maintained retinal para-inflammatory homeostasis and eventual recruitment and polarization of peripheral blood monocyte-derived macrophages (PBMDMs) into the retina can explain the phenotypic variability seen in this clinically heterogenous disease. Restoring glyco-immune checkpoint control with a sialic acid mimetic agonist targeting microglial/macrophage Siglecs to regain retinal para-inflammatory and inflammatory homeostasis is a promising therapeutic that could halt the progression of and improve visual function in all stages of macular degeneration. Full article
(This article belongs to the Special Issue Microglia and Astrocytes as Drug Targets)
Show Figures

Figure 1

Back to TopTop